Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention Academic Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Peptides
  • Platelet Aggregation Inhibitors

abstract

  • A novel higher-dose, double-bolus regimen of eptifibatide in coronary intervention attains and maintains >90% inhibition of platelet aggregation in >90% of patients, providing the pharmacodynamic construct for the design of the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial of adjunctive eptifibatide in coronary stent implantation.

publication date

  • July 24, 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11468201

Additional Document Info

start page

  • 406

end page

  • 11

volume

  • 104

number

  • 4